|
| Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Bullion ~ Forex ~ Sports ~ Technology ~ Health ~ Features |
| Lung Cancer ~ Lung Cancer ~ Breast Cancer ~ Heart attack ~ All Health Topics |
|
Home
/ Health News / 2008 / August 2008 / August 22, 2008 First trial to test new vaccine against multiple influenza strains successful |
Sack lunches may not provide adequate nutrients to preschooler
Packing lunch for your child might not be a good idea, for a new study has found that sack lunches may not regularly provide adequate nutrients for the growth and development of young children. ANI
Health-monitoring system helps maintain older adults well-being
Many older adults want to remain active and independent for as long as possible. Now, researchers from University of Missouri suggest that installing health monitoring system can help keep check on the health of the elderly and ensure their privacy. ANI
New drug shows potential to treat angina, other cardiac problems
A compound, designed to prevent chest pains in heart patients, could act as a drug to treat angina and possibly other cardiac pathologies, according to a study on animals. ANI
A new vaccine that could help fight several strains of influenza has passed its first phase of testing, according to researchers at the University of Texas at Galveston.
Washington, Aug 22 : A new vaccine that could help fight several strains of influenza has passed its first phase of testing, according to researchers at the University of Texas at Galveston.
Dr. Christine Turley, director of clinical trials and clinical research at the Sealy Center for Vaccine Development at UTMB and the study's principal investigator, said that VaxInnate's M2e universal vaccine could possibly protect against seasonal and pandemic influenza strains.
"We'd characterize this influenza vaccine candidate as very promising, based upon the immune responses and tolerability we saw in the clinical trial participants," Turley said.
"UTMB is committed to further studies of the vaccine candidate, which has the potential to be a safe, highly effective and much-needed option to prevent seasonal and pandemic influenza A," Turley added.
For the trial, researchers recruited 60 young adults in a double-blind, dose-escalating, first time in human, Phase I study to assess the safety and immunogenicity, or the ability to produce a response in the immune system, of the vaccine.
The trial was also designed to evaluate the methods used by VaxInnate to develop and produce flu vaccines.
The company uses a proprietary combination of toll-like receptor-mediated immune enhancement and recombinant bacterial production of vaccine antigen.
This proprietary technology could significantly decrease the time required to produce vaccine supplies sufficient to meet national demand, and provide a solution to international influenza vaccine needs which are unmet in all but the developed world.
The study will be presented at the Oct.25-28 joint meeting of the Interscience Conference on Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA).
ANI
